Pharmaceuticals News and Research

RSS

APP receives FDA approval to market Gemcitabine HCI for Injection, USP in 2 g dosage

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Gemcitabine HCI for Injection, USP, in the 2 g dosage strength. APP will launch this presentation of Gemcitabine immediately.

19 May 2011

Abbott RealTime PCR assay for measuring HCV viral load receives FDA marketing approval

Abbott announced today that it has received approval from the U.S. Food and Drug Administration to market its RealTime PCR (polymerase chain reaction) test for measuring the viral load of hepatitis C (HCV), the leading cause of liver cancer in the United States.

19 May 2011

Mpex, Synteract partner for cystic fibrosis fundraising event

Synteract, Inc., a full-service, global contract research organization, and Mpex Pharmaceuticals, a biopharmaceutical company developing new therapies to combat the growing issue of antibiotic resistance, have partnered for the second annual Great Strides fundraiser to benefit cystic fibrosis.

19 May 2011

Biothera begins dosing in Imprime PGG and cetuximab combination Phase III trial for colorectal cancer

Biothera began dosing patients today in a Phase III trial evaluating Imprime PGG in combination with cetuximab as a potential new treatment for recurrent or progressive KRAS wild-type colorectal cancer.

19 May 2011

Momentive Performance Materials collaborates with SSF to develop combination products

Momentive Performance Materials Inc. today announced a collaboration initiative with Specialty Silicone Fabricators (SSF) to develop combination products for medical devices manufacturers.

18 May 2011

MDxHealth reduces first quarter net loss by 17%

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, today issued its business update for the quarter ended March 31, 2011.

18 May 2011

Synergy expands GC-C agonist technology to lower cholesterol

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that it has successfully completed preclinical in vitro research demonstrating the inhibition of bile acid uptake by GC-C agonists and that it plans to commence animal studies shortly. Synergy believes this is the first time that GC-C agonists have been shown to potentially lower cholesterol.

18 May 2011

Study: 80% of U.S. physicians use Herceptin for HER2-positive metastatic gastric cancer treatment

In just over a month following the FDA's October 2010 approval of Roche's Herceptin for HER2-positive metastatic gastric cancer, more than 80 percent of U.S. physicians report using the drug, according to new research by GfK HealthCare.

18 May 2011

New denosumab Phase III trial data in high-risk prostate cancer presented at AUA conference

Data on the use of denosumab (Xgeva) to improve bone metastases-free survival in men with high-risk prostate cancer was presented at the American Urological Association conference today for the first time.

18 May 2011

Bill Gates calls for greater immunization efforts in World Health Assembly address

Bill Gates, co-chair of the Bill & Melinda Gates Foundation, on Tuesday called for a "Decade of Vaccines" in a keynote address at the World Health Assembly in Geneva, saying strengthening immunization programs against infectious diseases worldwide could save 10 million lives by 2020, Reuters reports.

18 May 2011

Bayer HealthCare to present results on investigational oncology compounds at ASCO annual meeting

Bayer HealthCare Pharmaceuticals, Inc. announced today that data evaluating several of its investigational oncology compounds will be presented in a scientific forum at the 2011 Annual Meeting of the American Society of Clinical Oncology, June 3-7, in Chicago, IL.

18 May 2011

Ampio's common stock to be listed on NASDAQ Capital Market

Ampio Pharmaceuticals, Inc., a clinical stage developer of new uses for previously approved drugs and new molecular entities, announces that its common stock has been approved for listing on the NASDAQ Capital Market.

18 May 2011

CITN selects Cytheris' CYT107 for initial clinical trials at network institutions

Cytheris SA and the Cancer Immunotherapy Trials Network, a new initiative in immunotherapy funded by the National Cancer Institute with its Central Operations and Statistical Center headquartered at Fred Hutchinson Cancer Research Center, Seattle, Washington, today announced the selection of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, as one of the first immunotherapeutic agents proposed for initial clinical trials at network institutions.

18 May 2011

WHO Director-General outlines vision for reform in World Health Assembly opening address

WHO Director-General Margaret Chan on Monday laid out her vision for reforming the international health agency in the opening address of the World Health Assembly in Geneva, saying she sees "a WHO that gives a bigger voice to the many partners working on health, but encourages them to speak with a coherent voice that responds, first and foremost, to the needs and priorities as defined by recipient countries," Intellectual Property Watch reports.

18 May 2011

NCNPR and Cancer Institute in Jackson partner for anti-cancer drug research

A new partnership to search for cancer-fighting drugs combines compound-identification and screening expertise at the University of Mississippi's National Center for Natural Products Research with the drug development and clinical-trials capabilities at the University of Mississippi Medical Center Cancer Institute.

18 May 2011

Endo and Bioniche present Urocidin Phase III trial preliminary results at 2011 AUA annual meeting

Endo Pharmaceuticals and Bioniche Life Sciences today presented Phase III trial results for the intravesical formulation of Mycobacterial cell wall-DNA complex (MCC), known as Urocidin, during a podium presentation at the 2011 American Urological Association annual meeting in Washington, D.C.

18 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, in Canada at St. Joseph's Healthcare - Hamilton, Ontario.

18 May 2011

Anacor Pharmaceuticals initiates AN2728, AN2898 Phase 2 trial in mild-to-moderate atopic dermatitis

Anacor Pharmaceuticals announced today that the first patient has been dosed in a Phase 2 trial of AN2728 and AN2898 to determine safety, tolerability and efficacy of the two compounds for the topical treatment of mild-to-moderate atopic dermatitis.

18 May 2011

Anti-cancer drug discovery partnership formed between UMMC Cancer Institute and Natural Products Center

A new partnership to search for cancer-fighting drugs combines compound-identification and screening expertise at the University of Mississippi’s National Center for Natural Products Research with the drug development and clinical-trials capabilities at the University of Mississippi Medical Center Cancer Institute.

18 May 2011

Bill Gates urges wiser vaccine coverage worldwide to save millions

Tuesday this week, Bill Gates called for strengthened immunization programs against infectious diseases to save 4 million lives by 2015 and 10 million lives by 2020, calling it the best possible investment in global health. He was addressing the annual assembly of the World Health Organization (WHO) in Geneva, attended by health ministers from the U.N. agency's 193 member states.

17 May 2011

Pharmaceuticals News and Research

APP receives FDA approval to market Gemcitabine HCI for Injection, USP in 2 g dosage

Abbott RealTime PCR assay for measuring HCV viral load receives FDA marketing approval

Mpex, Synteract partner for cystic fibrosis fundraising event

Biothera begins dosing in Imprime PGG and cetuximab combination Phase III trial for colorectal cancer

Momentive Performance Materials collaborates with SSF to develop combination products

MDxHealth reduces first quarter net loss by 17%

Synergy expands GC-C agonist technology to lower cholesterol

Study: 80% of U.S. physicians use Herceptin for HER2-positive metastatic gastric cancer treatment

New denosumab Phase III trial data in high-risk prostate cancer presented at AUA conference

Bill Gates calls for greater immunization efforts in World Health Assembly address

Bayer HealthCare to present results on investigational oncology compounds at ASCO annual meeting

Ampio's common stock to be listed on NASDAQ Capital Market

CITN selects Cytheris' CYT107 for initial clinical trials at network institutions

WHO Director-General outlines vision for reform in World Health Assembly opening address

NCNPR and Cancer Institute in Jackson partner for anti-cancer drug research

Endo and Bioniche present Urocidin Phase III trial preliminary results at 2011 AUA annual meeting

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

Anacor Pharmaceuticals initiates AN2728, AN2898 Phase 2 trial in mild-to-moderate atopic dermatitis

Anti-cancer drug discovery partnership formed between UMMC Cancer Institute and Natural Products Center

Bill Gates urges wiser vaccine coverage worldwide to save millions

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence